Crestor vs Leqvio: Cost and Access Head-to-Head

Why This Comparison Matters Now

Rosuvastatin and inclisiran represent two different generations of lipid-lowering therapy, and the cost gap between them is enormous. Patients searching for the best way to lower LDL-C need clarity on what each drug actually delivers relative to its price tag.

Rosuvastatin (brand name Crestor) is a high-intensity statin that has been generic since 2016. It remains the most-prescribed statin by potency class in the United States, with over 28 million prescriptions dispensed annually according to IQVIA data reported by the FDA. Inclisiran (Leqvio), a small interfering RNA (siRNA) targeting PCSK9 synthesis in the liver, received FDA approval in December 2021. It works by a completely different mechanism: rather than blocking cholesterol synthesis via HMG-CoA reductase the way statins do, inclisiran silences the gene that produces PCSK9, allowing more LDL receptors to clear cholesterol from the bloodstream [1].

No head-to-head randomized trial has compared rosuvastatin directly with inclisiran. The data below are synthesized from separate trials. Direct comparisons of effect size should be interpreted with caution.

LDL-C Lowering: What the Trials Show

Rosuvastatin at 20 to 40 mg daily lowers LDL-C by 45 to 55% from baseline as monotherapy, depending on the dose and population studied. In the JUPITER trial (N=17,802), rosuvastatin 20 mg reduced median LDL-C from 108 mg/dL to 55 mg/dL, a 50% reduction [2].

Inclisiran works differently. It is not designed to replace statins but to stack on top of them. In the pooled ORION-10 and ORION-11 trials (combined N=3,178), inclisiran 284 mg given subcutaneously at day 1, day 90, and then every 6 months reduced LDL-C by an additional 49.2 to 52.3% compared with placebo, on top of maximally tolerated statin therapy [1]. That means a patient already taking rosuvastatin 40 mg who adds inclisiran could see their LDL-C drop by roughly another half. For someone starting at an on-statin LDL of 100 mg/dL, that could bring levels near 50 mg/dL.

The American Heart Association and American College of Cardiology 2018 cholesterol guidelines recommend high-intensity statins as first-line therapy for patients with atherosclerotic cardiovascular disease (ASCVD). PCSK9-targeted agents, including inclisiran, are positioned as add-on therapy for patients who do not reach LDL goals on maximally tolerated statins [3].

Cardiovascular Outcomes: Proven vs Pending

This is where rosuvastatin holds a major advantage. It has hard outcomes data.

JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) randomized 17,802 apparently healthy men and women with LDL-C <130 mg/dL and high-sensitivity C-reactive protein (hsCRP) ≥2 mg/L to rosuvastatin 20 mg or placebo. The trial was stopped early at a median follow-up of 1.9 years because rosuvastatin reduced the primary composite endpoint of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death by 44% (HR 0.56; 95% CI 0.46, 0.69; P<0.00001) [2].

Inclisiran does not yet have a completed cardiovascular outcomes trial. ORION-4, a large (N≈15,000) randomized outcomes study comparing inclisiran with placebo in patients with established ASCVD, is ongoing with results expected in 2026 [4]. Until ORION-4 reports, prescribers are extrapolating from the LDL-lowering magnitude and from the outcomes data of PCSK9 monoclonal antibodies (evolocumab in FOURIER, alirocumab in ODYSSEY OUTCOMES) rather than from direct inclisiran evidence.

"We have strong biological plausibility and strong LDL-lowering, but the outcomes trial is the final piece," noted the Endocrine Society's 2023 lipid management position statement.

Cost Breakdown: Generic Statin vs Branded Biologic

The cost difference is not subtle. Generic rosuvastatin is one of the cheapest prescription medications in the United States. A 30-day supply of rosuvastatin 20 mg ranges from $4 at discount pharmacies to approximately $30 at retail without a coupon, according to GoodRx and CMS pricing data. Annual cost: $48, $360.

Leqvio carries a wholesale acquisition cost (WAC) of approximately $6,500 per injection. After the loading protocol (injections at day 0, day 90, and every 6 months thereafter), year-one cost is roughly $19,500 (three injections), and subsequent years run approximately $13,000 (two injections). Even with manufacturer copay assistance, out-of-pocket spending depends heavily on the payer.

Because Leqvio is administered by a healthcare professional in an office or infusion center, it is billed under the medical benefit (Medicare Part B, or commercial medical) rather than the pharmacy benefit. This billing pathway creates a distinct set of coverage rules, copay structures, and prior-authorization requirements compared with a pill picked up at a pharmacy counter.

A 2023 Institute for Clinical and Economic Review (ICER) analysis estimated that inclisiran would need to be priced between $3,600 and $5,000 per year to align with conventional cost-effectiveness thresholds of $100,000, $150,000 per quality-adjusted life year (QALY) gained, well below its current WAC [5]. The National Heart, Lung, and Blood Institute has echoed the need for value-based pricing of novel lipid-lowering agents to expand access.

Insurance Coverage and Prior Authorization

Rosuvastatin requires no prior authorization on any major formulary. It sits on the lowest tier of every commercial, Medicare Part D, and Medicaid drug list in the country. Patients with high-deductible plans can use manufacturer or pharmacy discount cards to keep costs under $15 per month.

Leqvio coverage is more complicated. Because it is a physician-administered drug:

• Medicare Part B covers Leqvio with a buy-and-bill model. Physicians purchase the drug, administer it, and bill CMS. Patient responsibility is typically 20% coinsurance after meeting the Part B deductible, which could mean $1,300 or more per injection without supplemental coverage. Prior authorization is not required by Medicare nationally, but some Medicare Advantage plans do require it.
• Commercial insurance varies widely. Most large plans cover Leqvio but require prior authorization documenting statin intolerance, inadequate LDL response on maximally tolerated therapy, or both. Step-therapy protocols may require a trial (and failure) of ezetimibe and sometimes a PCSK9 monoclonal antibody before approving inclisiran.
• Medicaid coverage varies by state. Some states have added inclisiran to preferred drug lists; others have not. Patients on Medicaid should expect prior-authorization requirements.

Novartis operates a patient support program (Leqvio Complete) that provides copay assistance for eligible commercially insured patients, potentially reducing out-of-pocket costs to $0 per injection. Patients covered under government insurance (Medicare, Medicaid, Tricare) are not eligible for copay cards, per federal anti-kickback statute restrictions [6].

Who Should Take Which Drug

The decision tree is straightforward for most people. Rosuvastatin (or another high-intensity statin like atorvastatin) is first-line for nearly every patient who needs LDL-C lowering. The ACC/AHA guidelines are explicit: high-intensity statin therapy should be the foundation [3].

Inclisiran enters the picture when statins alone are not enough. That includes patients with:

• Heterozygous familial hypercholesterolemia (HeFH) who cannot reach LDL targets on statin plus ezetimibe
• Established ASCVD with very high risk who remain above LDL 70 mg/dL on maximally tolerated therapy
• True statin intolerance confirmed after trials of at least two different statins at the lowest dose, where inclisiran can serve as a non-statin LDL-lowering backbone

For patients with documented statin intolerance, inclisiran provides a convenient dosing schedule. Two injections per year (after loading) eliminates daily pill burden and the adherence challenges that come with it. A post-hoc analysis of ORION-9, -10, and -11 found that inclisiran maintained consistent LDL-C reductions across all dosing intervals, with no attenuation of effect, suggesting durable adherence by design [1].

Adherence and Practical Considerations

Statin non-adherence is a real clinical problem. A 2022 meta-analysis published in the European Heart Journal estimated that roughly 50% of patients prescribed statins discontinue them within one year. Reasons range from perceived side effects (myalgia is reported by 5 to 10% of statin users, though nocebo effects account for a substantial proportion per the SAMSON trial [7]) to simple forgetfulness.

Inclisiran's twice-yearly in-office injection model eliminates the daily adherence question entirely. If a patient shows up for the injection, the drug works for six months. This "healthcare-professional-administered" design may be especially useful for populations with low medication adherence rates.

The tradeoff: every dose requires an office visit. For patients in rural areas or those with limited transportation, traveling to a clinic twice a year for an injection adds a logistical barrier that a $10 monthly pill does not.

Rosuvastatin's side-effect profile is well characterized over two decades: myalgia (5 to 10% reported, ~1 to 2% causally attributable), elevated hepatic transaminases (<1%), and a small increase in new-onset diabetes (HR 1.25 in JUPITER, primarily in those with pre-existing metabolic risk factors) [2]. Inclisiran's injection-site reactions occurred in 5% of patients in ORION trials vs 0.7% for placebo, and were predominantly mild. No hepatotoxicity signal emerged in phase III data [1].

The Bottom Line on Value

Rosuvastatin delivers a 44% reduction in major cardiovascular events at under $400 per year. That is among the highest value-per-dollar ratios in all of medicine. Inclisiran offers potent add-on LDL reduction and a unique dosing convenience, but at a price point that remains 30, 50 times higher annually, and without its own completed cardiovascular outcomes trial.

For a patient already on rosuvastatin 40 mg plus ezetimibe 10 mg who still has an LDL-C of 85 mg/dL and a history of two myocardial infarctions, adding inclisiran could bring LDL-C near 40 mg/dL. That added reduction could translate to meaningful risk reduction based on the log-linear relationship between LDL-C and ASCVD events described in Cholesterol Treatment Trialists' Collaboration data [8]. Whether the $13,000 annual price tag is justified for that particular patient depends on payer willingness, patient access, and, soon, what ORION-4 reveals.

The ACC Expert Consensus Decision Pathway for non-statin therapies states: "For patients with clinical ASCVD at very high risk whose LDL-C remains ≥70 mg/dL on maximally tolerated statin and ezetimibe therapy, adding a PCSK9 inhibitor is reasonable" [3]. Inclisiran now occupies that same clinical niche.

Generic rosuvastatin 20 mg daily remains the starting point for LDL management at a cost of $0.33 per day. Inclisiran at $35.62 per day adds a powerful second mechanism for the subset of patients who need it most.